...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What's the deal with Zenith?

And of course, this whole thing (as proposed by Don M.) is based on the premise that BOM2 will be a success so that Resverlogix will be able to pay its debt to Zenith and for Zenith C C to collect on the Resverlogix Royalty Preferred Shares.

Don sounded firm on this scenario, as a way of funding Resverlogix, BOM2 via Zenith et al. as if he can do it unilaterally without the approval of the Zenith Shareholders. 

 

Koo

Share
New Message
Please login to post a reply